Codexis Enters Into Research Collaboration With Schering-Plough
According to Codexis, the company's unique MolecularBreeding(TM) protein and strain engineering technology platform creates superior biological catalysts (biocatalysts) -- either enzymes or fermentation strains -- crafted specifically for cutting-edge chemical processes that can enable pharmaceutical process development, shorten process development timelines, dramatically improve existing manufacturing processes and increase chemical development productivity. Codexis estimates that its platform technology can reduce cost of goods by 35% - 65% and capital expenditures by over 35%. In addition, this platform technology can create new intellectual property opportunities, which can help extend the lifetime of drug products.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.